{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015792","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.537138+00:00","generated_at":"2026-06-03T09:56:15.833460+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Abeona shareholders approve equity plan increase to 3.2M shares; re-elect two directors","bullets":["A&R 2023 Equity Incentive Plan approved, increasing shares reserved from 1.7M to 3.2M (1.5M new shares).","Leila Alland and Vishwas Seshadri re-elected as Class 2 directors with overwhelming support.","Advisory vote on named executive officer compensation approved: 9,529,727 for, 402,844 against.","Ratification of Deloitte & Touche as independent auditor for FY2024 approved: 14,720,159 for."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015792","json":"https://secwatch.observer/filing/0001493152-24-015792.json","markdown":"https://secwatch.observer/filing/0001493152-24-015792.md","text":"https://secwatch.observer/filing/0001493152-24-015792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:56:15.833460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"427c22e83195be5c655bafff12bee52519416545","claim":"ABEONA THERAPEUTICS INC. shareholders approved Election of Directors at the 2024-04-24 meeting.","evidence_excerpt":"Leila Alland and Vishwas Seshadri were elected to serve as Class 2 directors of the Company until the 2027 annual meeting of stockholders and until their successors are elected and qualified. The results of the election of directors are as follows: Nominee Votes Non-Votes Leila Alland 8,985,852 958,122 12,938 5,093,839 Vishwas Seshadri 9,922,210 21,390 13,312 5,093,839","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-24"}],"fact_type":"shareholder_vote"},{"claim_id":"55499a1b2bf8ad3d5cff231ba0250af3c4a622cd","claim":"ABEONA THERAPEUTICS INC. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm at the 2024-04-24 meeting.","evidence_excerpt":"A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 was approved by the following votes: Votes Non-Votes 14,720,159 136,942 193,650 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-24"}],"fact_type":"shareholder_vote"},{"claim_id":"5eecae1659b6b8e8780bfa8ae1dd4d725a3b4ac9","claim":"ABEONA THERAPEUTICS INC. shareholders approved Approval of an Increase in the Number of Shares Reserved for Issuance Under the A&R Plan at the 2024-04-24 meeting.","evidence_excerpt":"A proposal to approve an increase in the number of shares reserved for issuance under the A&R Plan from 1,700,000 to 3,200,000 shares was approved based on the following votes: Votes Non-Votes 9,358,912 570,314 27,686 5,093,839","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-24"}],"fact_type":"shareholder_vote"},{"claim_id":"e9b8a3c0643c7012a440b4c6b9d9e56572c07130","claim":"ABEONA THERAPEUTICS INC. shareholders approved Advisory Vote on Compensation of Named Executive Officers at the 2024-04-24 meeting.","evidence_excerpt":"An advisory vote to approve the compensation of the Company’s named executive officers was approved by the following votes: Votes Non-Votes 9,529,727 402,844 24,341 5,093,839","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-24"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}